![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
ATX01 (amitriptyline hydrochloride) topical which is investigated in Phase 2 for pain of Erythromelalgia, a rare neurological and vascular disease characterized by painful extremities for which there is no available treatment. The trial is due to read out in H1 2024.
Lead Product(s): Amitriptyline Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Product Name: ATX01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
The net proceedings will be used to demonstrate the clinical efficacy of ATX01 (amitriptyline hydrochloride) in Phase 2 in chemotherapy-induced peripheral neuropathy and erythromelalgia.
Lead Product(s): Amitriptyline Hydrochloride
Therapeutic Area: Product Name: ATX01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Relyens Innovation Santé
Deal Size: $21.2 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 14, 2023
Details:
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments.
Lead Product(s): Chlordiazepoxide,Amitriptyline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Limbitrol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: MedQuímica Indústria Farmacêutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 28, 2022
Details:
The ANDA approval is for Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the USFDA to market a generic version of ELAVIL (Amitriptyline Hydrochloride) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg of AstraZeneca Pharmaceuticals LP.
Lead Product(s): Amitriptyline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021